Bringing Advanced Theranostics Within Reach.
What is Theranostics?
Theranostics combines precise, molecular‑level imaging with targeted therapies to deliver truly personalized cancer care.
By using diagnostic scans to pinpoint tumors and then deploying treatments engineered to seek out those same molecular markers...
Theranostics is designed to maximize treatment precision while helping preserve healthy tissue.
Our Approach
PurCura builds and runs the operational engine behind theranostics programs—managing coordination, workflows, logistics, and payer support—so everything moves faster, smoother, and more reliably for both patients and partners.
“It’s kind of a dream for cancer therapy.”
— Dr. Frankis Almaguel, Director of Nuclear Medicine
Precision Imaging + Targeted Radiotherapy creates
One Seamless Outpatient Procedure
Pluvicto®. FDA Approved.
About:
On March 28, 2025, the FDA broadened the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto®) to include patients with PSMA‑positive metastatic castration‑resistant prostate cancer who have progressed on one ARPI and are appropriate to delay taxane‑based chemotherapy. This decision was driven by the Phase III PSMAfore trial, in which Pluvicto® more than doubled median radiographic progression‑free survival (11.6 months vs. 5.6 months) and cut the risk of progression or death by 59% versus a switch in ARPI. Delivered as a 30‑minute outpatient infusion with predominantly Grade 1–2 side effects, this landmark approval offers patients earlier access to a highly targeted therapy that delays chemotherapy and enhances quality of life.